Colorectal cancer (CRC) develops through the accumulation of both genetic and epigenetic alterations. However, while the former are already used as prognostic and predictive biomarkers, the latter are less well characterized. Here, performing global methylation analysis on both CRCs and adenomas by Illumina Infinium HumanMethylation450 Bead Chips, we identified a panel of 74 altered CpG islands, demonstrating that the earliest methylation alterations affect genes coding for proteins involved in the crosstalk between cell and surrounding environment. The panel discriminates CRCs and adenomas from peritumoral and normal mucosa with very high specificity (100%) and sensitivity (99.9%). Interestingly, over 70% of the hypermethylated islands resulted in downregulation of gene expression. To establish the possible usefulness of these non-invasive markers for detection of colon cancer, we selected three biomarkers and identified the presence of altered methylation in stool DNA and plasma cell-free circulating DNA from CRC patients.
Introduction
Colorectal cancer (CRC), the third most prevalent cancer in the world, 1 develops over years or decades, as a result of the accumulation of genetic and epigenetic alterations. At least three distinct types have been described (1) chromosomal instability (CIN), the most frequent (80-85%), is characterized by aneuploidy, chromosomal gains/losses and accumulation of mutations in specific oncogenes (e.g., KRAS, PIK3CA and BRAF) and tumor suppressors genes (e.g., APC, SMAD4, TP53); (2) microsatellite instability (MSI), caused by dysfunction of DNA mismatch repair genes; (3) CpG island methylation phenotype (CIMP), characterized by a widespread CpG island methylation, accounting for about 20-40% of CRCs. These types are not mutually exclusive, with tumors exhibiting features of more than one. 2 Although CIN tumors are characterized by mutations in oncogenes and tumor suppressor genes, epigenetic changes may also play a relevant role in neoplastic transformation even at the earliest stages. [3] [4] [5] Better knowledge of these epigenetic alterations could also help clarify which cellular processes are affected by such early changes and drive future functional studies.
Genes altered by methylation not only might represent potential biomarkers for early detection of CRC, 6 but could also be important prognostic and predictive markers to improve therapeutic interventions. 7, 8 Indeed, therapies based on epigenetic reprograming have been recently tested in several types of tumors. 9, 10 Moreover, since the screening of epigenetic alterations can also be carried out in circulating tumor DNA (ctDNA) and in DNA isolated from feces of patients at risk of CRC, the detection of these biomarkers through less invasive procedures makes their identification of great value. 8 The aims of our study were (i) to identify signature alterations in the CRC methylome through over 485 K CpG loci of CRCs and peritumoral tissues; (ii) to test whether these alterations represent early events in CRC development; (iii) to explore the use of non-invasive techniques (stool and ctDNA) to reveal altered methylation. We identified the most altered pathways since early stages of CRC tumorigenesis and defined a panel of CpG islands differentially methylated as biomarkers capable to detect CRC even at its earliest stages. This panel was successfully cross-validated in silico using methylation data from >500 CRC samples. Selected biomarkers were then confirmed in ctDNAs and in DNAs from stool samples of CRC patients.
Materials and Methods

Samples collection and processing
Samples for whole genome methylation analysis. The methylome analysis was first performed in 18 pairs of primary CRCs among which four had matched peritumoral samples, taken at a distance of >10 cm from the neoplastic tissue (selected to represent the four anatomic region affected by cancer: left, right, sigmoid colon, rectum). Specimens came from patients diagnosed with CRC and operated at the Department of General Surgery, University of Cagliari (Italy) ( Fig. 1 and Supporting Information Table S1 ). For our study, cases with familial adenomatous polyposis or human nonpolyposis colorectal cancer were excluded.
In a second step, methylome analysis was conducted in 21 adenomas and three matched intestinal mucosa controls, from 21 patients bearing an adenoma ( Fig. 1 and Supporting Information Table S2 ). Lesions were removed during endoscopy.
11 DNA samples were collected at the National Institute for Cancer Research of Genoa (Italy).
Stool samples for methyl-BEAMing analyses. Stool samples were collected from 24 patients with colorectal cancer and taken intraoperatively from the bowel resection specimen. All stools samples were immediately frozen after collection and stored at 2808C until being processed. DNA extraction was performed using the QIAamp DNA Stool Mini Kit according to the manufacturer's instructions. All samples were collected at Department of Surgical Sciences, University of Cagliari and Department of Clinical and experimental medicine, University of Sassari (Fig. 1 ).
Plasma samples for methylBEAMing analyses. Blood draws were collected from 45 cases of CRC enrolled at the medical oncology department of the Candiolo Cancer Institute-FPO, IRCCS (Torino, Italy) between November 2015 and April 2016. Twelve cases were under adjuvant therapy after surgical resection of their lesion and were considered with no evidence of disease (NED). Remaining cases (N 5 33) were metastatic CRC with different levels of tumor burden (Fig. 1) . Whole blood was processed within samples 3 hr after collection. Samples were centrifuged at 1,600g for 10 min for phase separation. Plasma was collected and submitted to a second centrifugation step at 3,000g for 10 min to remove platelets and cell debris. Upper phase was collected, aliquoted and stored at 2808C until further processing. One milliliter of plasma was processed for DNA extraction using the MaxwellV R RSC ccfDNA Plasma Kit (Promega, Madison, WI, USA) using 100 ml for the elution volume.
Samples for real-time qRT-PCR validation. A total of 26 RNA samples (eight CRC with matched peritumoral tissues and ten individual CRCs), extracted as described in the previous paragraph, were tested by qRT-PCR (Fig. 1 ).
What's new?
Colorectal cancer (CRC) develops through the accumulation of both genetic and epigenetic alterations. However, while genetic alterations are already used as prognostic and predictive biomarkers, epigenetic alterations are less well characterized. Here, the authors identified and validated a panel of 74 altered CpG islands able to discriminate CRCs and adenomas from peritumoral and normal mucosa with very high specificity and sensitivity. Three selected markers were tested and detected through non-invasive techniques, both in circulating tumor DNA and in stool DNA. The earliest methylation alterations affected genes coding for proteins involved in the crosstalk between tumor cells and their surrounding environment.
Cancer Genetics and Epigenetics MethylBEAMing analysis. The primers used for pyrosequencing were coupled with Tag sequence as previously described. 9 Two microliters of bisulfite converted cfDNA was amplified in replicate and processed following the same protocol previously described 10 (Supporting Information Table S3 ). Purified beads were run on a BD Accuri C6 (Becton-Dickinson, Franklin Lakes, NJ, USA), methylation percentage was expressed as the number of events in the methylated gate divided by the sum of events in methylated and unmethylated gates multiply by 100.
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Markers selection for validation of locus specific methylation alterations. We selected three CpG islands, based on both a large methylation D between tumor and non-tumor tissue and the feasibility of the assay. Thirteen regions belonging to the biomarker panel identified were selected for locus specific investigation. Since cell free circulating and stool DNA is known to be composed of short fragments, 12 significant probes which were distant from a maximum of 150 bp (defining 23 loci) were selected to assess their potential to discriminate tumors from normal tissue in The Cancer Genome Atlas (TCGA) COREAD cohort using ROC analyses. Ten loci demonstrated a positive predictive value of 1 and a negative predictive value of at least 0.5. Among those, three regions allowed methylation independent amplification assay with highly specific probe design (GRIA4, SLC8A1, SYN3) (Supporting Information Table S4 ) and were firstly validated in a second data set of 78 tumoral and matched peritumoral tissue samples by pyrosequencing analysis (see Supplementary Materials and Methods).
Statistical analysis
Power calculation. The power was estimated on the calculation of the parameters of interest using the GSE48684 dataset. Based on this preliminary data the number of samples was calculated assuming an effect size that consider a differential methylation level of at least 10%, using a type I error of 10e-8 (which takes into account the need to correct for multiple test) and a statistical power of 0.8. Using these criteria, the number of samples to be analyzed should be 30.
Methylome data management. Illumina Methylation 450 K raw data were analyzed using the RnBeads analysis software package, as previously described. 13, 14 In addition to CpG sites, four sets of genomic regions were covered in the analysis (tiling, genes, promoters and CpG Islands). Corrected pvalues (Benjamini & Hochberg) were computed as previously described. 13, 14 The selected differently methylated CpG loci were annotated, by referring to the 450 K manifest, to obtain a gene list based on HGNC database. The beta values obtained for each sample at each CpG locus analyzed, were used in an analysis of Unsupervised Hierarchical Clustering (UHC), that, comparing locus to locus, allows to trace a tree (called dendrogram) whose closest branches indicate the most similarity in the methylation pattern, and vice versa. Finally, beta values were also visualized by building a HeatMap.
Biomarker specificity and sensitivity evaluation. We evaluated in three datasets (discovery set, GSE48684, TCGA COREAD) the tumoral and non-tumoral beta value distribution relative to the 74 biomarkers. The combined p-values of each biomarker was obtained using the Fisher's method, by combining the p-values of each CpG site belonging to a particular CpG island, calculated using the Wilcoxon test.
To evaluate the association of each biomarker with a binary outcome a logistic regression model was fitted to the individual biomarker data and the new probabilities used to calculate the area under the curve (AUC), specificity and sensitivity values using the "OptimalCutpoints" package. 15 To evaluate the ability of the entire biomarkers panel to correctly classify between two possible conditions (i.e., tumoral vs. non-tumoral), we built a support vector machine learning model (SVM), using the GSE48684 dataset as a training set and the TCGA COREAD as test set and evaluate the prediction performance ability in the test set calculating the confusion matrix using the "caret" package.
Bioinformatic analysis. Functional annotations of the differently methylated loci, were conducted by the ToppGene package, 16 from which are derived the information on the pathways potentially involved. The significance value was corrected for multiple comparisons (Bonferroni or Benjamini & Hochberg).
Three cross-validation datasets were retrieved from the database NCBI Gene Expression Omnibus (GEO) portal (http://www.ncbi.nlm.nih.gov/geo/) under accession numbers GSE48684, GSE52270, GSE53051. Processed data were used for all datasets aforementioned. TCGA COREAD cohort is available online at RnBeads website under Methylome Resources (http://rnbeads.mpi-inf.mpg.de/methylomes.php). For each of these datasets the mean methylation value for each CpG island of interest has been calculated and visualized using Bioconductor package "ComplexHeatmap." 17 Cancer Genetics and Epigenetics 
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Results
CRC methylome alterations are early events in colon carcinogenesis: identification of an early epigenetic biomarkers panel
The differential methylation analysis conducted on 18 CRCs and 4 peritumoral samples ( Fig. 1 and Supporting Information Table S1 ), powerfully discriminated tumor samples from peritumoral tissues. We identified 22307 CpG loci differentially methylated with an adjusted p-values threshold of 0.05 (Benjamini & Hochberg multiple test correction). To test whether these alterations represent an early event in carcinogenesis, we conducted a differential methylation analysis on 21 adenomas vs. 3 control mucosae ( Fig. 1 and Supporting Information Table S2 ). As expected, the results of the analysis in adenomas were less robust than in CRCs. Using the nominal threshold (p-values <0.05), 43999 CpG loci resulted differently methylated. In both CRCs and adenomas, a wide hypomethylation of the tumoral samples was found by analyzing the entire genome, divided into portions (tiling), however, by restricting the analysis to the regulatory regions, a switch toward hypermethylation, especially in the CpG islands, was evident (Figs. 2a and 2b) .
The list of genes whose associated CpG islands, were significantly altered (875 in CRCs and 2,393 in adenomas), was subjected to a gene enrichment and candidate gene prioritization analysis by Toppgene, allowing the identification of the pathways most affected by aberrant methylation: Wnt signaling, Neuronal System, Cadherin signaling, Transmission across Chemical Synapses, Neuroactive ligand-receptor interaction, Neurotransmitter Release Cycle, GABAergic synapse, Core extracellular matrix, Calcium signaling, Cholinergic synapse (Supporting Information Table S5 ). For the list of the 171 genes found modified in CRCs and 432 in adenomas belonging to 10 significantly involved pathways, see Supporting Information Table S6 . Notably, Toppgene results show that the most affected pathways were largely comparable between CRCs and adenomas (Fig. 2c) .
Remarkably, most of the genes whose associated CpG islands were altered in CRCs, were "already" aberrant in adenomas. In Figure 3 and Supporting Information Table S7 are listed 74 CpG islands resulting from the comparison, with the respective average beta values and Ds calculated between the average value in the tested samples (CRCs or adenomas) and in the respective controls. Interestingly, only two islands, at GNG7 and GRIN3B genes, underwent hypomethylation in both adenomas and CRCs. Of note, the D average beta value was always higher in CRCs than in adenomas (except for EDNRB), probably due to a greater methylation heterogeneity among adenomas. Surprisingly, none of the genes listed in Figure 3 resulted dysregulated by the transcriptome analysis. However, all those genes displayed an extremely low level of expression, close to the background intensity level. Therefore, an investigation by qRT-PCR was undertaken (Supporting Information Fig. S1 ). UHC was conducted on the CRCs and adenomas (Fig. 3) discovery set, based on the 74 biomarkers panel. A multi-cluster gene functional enrichment analysis conducted only for the genes associated with the 74 CpG islands, showed a significant enrichment of proteins involved in the crosstalk between cell and surrounding environment (see Figs. 3 and 4) .
In silico validation of the CRC early biomarkers panel: specificity for primary tumors and metastases To validate and increase the statistical power of our discovery dataset results, first, we cross-validated in silico our set of markers, as predictors of cancer and adenoma, using methylation data from two databases (I) TCGA COREAD cohort 18 ( Fig. 5a ) and (II) GSE48684 3 (Fig. 5b) . The 74 biomarker panel was able to separate most carcinomas and adenomas from normal mucosa. ROC analysis was performed for each RnBeads differential methylation analysis performed on the data obtained using Infinium HumanMethylation450 BeadChip, for single CpGs and for sets of pre-defined genomic regions such as genome-wide 5 kb tiling regions, genes, promoters and CpG islands, in CRC vs. peritumoral tissue samples. Each dot represents the average beta value (methylation value) for each CpG locus in the region, resulting from the average of the samples belonging to that group; in red are those significantly differentially methylated. The pathways significantly altered are shown (in descending order of significance), according to the functional annotation analysis performed by ToppGene package. This analysis was conducted on the genes corresponding to the CpG islands significantly altered, according to the 450 K manifest. The outputs generated by ToppGene show: the number of genes belonging to the pathway, the number of altered genes belonging to the pathway, and significance levels, raw and corrected for multiple testing according to Bonferroni marker using TCGA COREAD cohort. The specificity of many markers was equal to 1, i.e. 100% (ranging from 0.89 to 1), the sensitivity was 0.9 in over 70% of the islands (ranging from 0.7 to 0.97) (Supporting Information Tables S7  and S8 ). The robustness of the identified biomarkers was supported by p-values lower than the threshold for claiming genome-wide significance (p < 10
28
). We also evaluated the specificity, sensitivity, AUC and accuracy for the entire panel, obtaining respectively: SP 5 1; SE 5 0.9942; AUC 5 1; ACC 5 0.9971.
To verify if the panel is specific for CRC, we examined the GSE52270 data set. 19 The panel resulted specific for CRC, but not for the other analyzed cancer types (Fig. 5c) .
Interestingly, the UHC of our CpG islands panel in a fourth data set (GSE53051), 20 assigned colon cancer metastases on the same branches of CRC, with the exception of two cases (Fig. 5d) . These results suggest that these alterations are not counter-selected during carcinogenesis and are maintained in metastases.
Methylation analysis in stool DNA samples
Based on the consistency of the methylation alterations identified in the tumor tissues, we wondered whether these methylation patterns could be detected in DNA extracted from stools. The goal was to set up in CRC patient stools the experimental test as a possible non-invasive technique to detect early/asymptomatic CRCs. We selected three CpG islands, associated with GRIA4, SLC8A1 and SYN3 genes, based on both a large methylation D between tumor and non-tumor tissue and the feasibility of the assay experimental MethylBEAMing methylation values in cfDNA, isolated from plasma, for GRIA4, SLC8A1 and SYN3. Samples were divided into three groups: NED, CEA-low and CEA-high, using a threshold of 5 ng/ml. (c) Graph showing the percentages of genetic and methylation alterations detected in plasma (left y-axis) and CEA levels (right y-axis) for all samples, divided into NED, CEA-low and CEA-high. All shown comparison were performed using Mann-Whitney U-test. Asterisks indicate the significance level: *p < 0.05; **p < 0.01. Table S4 ). To assess the reproducibility of the three selected markers, we performed a methylation analysis by pyrosequencing in a second data set of 78 tumoral and 78 matched peritumoral samples (Fig. 1) . All three selected islands, associated with GRIA4, SLC8A1 and SYN3 genes, were significantly hypermethylated in tumor vs. peritumoral samples (Supporting Information Fig. S2) . Methylation of the same CpG islands, was thus assessed, by digital PCR analyses, in DNA isolated from CRC patients' stool samples, taken at the time of surgical resection. As shown in Figure 6a , all except three tested samples (87.5%) showed >1% of methylation for at least one of the three markers. In particular, 79.2% of samples showed >1% of methylation at GRIA4 (average 21%); 70.8% at SLC8A1 (average 10%); 62.5% at SYN3 (average 13%).
design (Supporting Information
Methylation analysis in ctDNA
Tumor fragments of DNA in the blood stream can be used as a surrogate sample to tissue biopsy. Cell free circulating DNA is a mixture of nucleic acids from normal (mainly from leukocytes) and from tumor tissues (ctDNA) 21 Liquid biopsy test using genetic or epigenetic alterations in plasma DNA has been proposed for early diagnosis 6 and early detection of relapse.
22-24
Methylation of GRIA4, SLC8A1 and SYN3 was assessed in circulating DNA of CRC patients. Assays were successful in at least one replicate for 43, 45 and 41 cases for GRIA4, SLC8A1 and SYN3, respectively. Some patients were receiving adjuvant therapy post-surgical resection of their tumor with no radiologic evidence of disease (NED) and were expected to display very low or no ctDNA. The aim of these exploratory analyses was to compare methylation levels at the three loci between NED and patients still bearing a lesion. Median methylation at GRIA4 and SLC8A1 was significantly different (U-test, GRIA4: p-values 50.029; SLC8A1: p-values 50.024). SYN3 did not show any difference, possibly due to low number of cases which displayed methylation. The positivity exclusively seen in patients with lesions demonstrates the specificity of the selected markers.
Among clinical features (Supporting Information Table  S9 ), CEA levels, a surrogate of tumor burden, could discriminate two subgroups among the patients still bearing a lesion. According to the literature, we divided the samples into three groups: NED, CEA-low and CEA-high, using a threshold of 5 ng/ml; indeed, CEA elevation over 5 ng/ml was found to be a very accurate marker of recurrence. 25 As shown in Figure 6b, dividing the samples in the three groups, did not result in significant differences between NED and CEA-low, relatively to the observed methylation levels, while significantly higher methylation levels (p-values 5 0.00223 and pvalues 5 0.01972, respectively) were evident for GRIA4 and SLC8A1 in the CEA-high group. Of note, patients with low CEA whose primary tumor was mutated for RAS or BRAF, did not display the genetic alteration in ctDNA (Fig. 6c) .
Interestingly, the three NED subjects with high levels of CEA, did not show hypermethylation in ctDNA.
Discussion
The genetic and epigenetic landscape of CRC has been extensively studied so far. However, current technological advances in DNA methylation analysis have enabled the identification and validation of new biomarkers in a more unbiased way. Nevertheless, the concept of CIMP phenotype remains debated, 26 mostly due to lack of consensus in its evaluation warranting unbiased genome-wide approaches to characterize epigenetic changes involved in CRC onset and development. 4 We observed limited correlation between CIMP phenotype and hypermethylation of the CpG islands included in our panel, perhaps because we selected loci as being the most informative on the early alterations, or perhaps because CIMP was classically defined on methylation alterations discovered before the advent of genomic approaches to assess global methylome.
Although several studies have been conducted analyzing methylome alterations in CRCs, there remains urgent need for biomarker discovery. In our work, we identified a panel of 74 CpG islands aberrantly methylated not only in advanced stages of disease, but also detectable in adenomas, when the tumor is often asymptomatic. The performance ability of the panel was cross-validated in silico by analyzing it in hundreds of samples, including CRCs, adenomas, normal counterparts and other tumor types. The identified panel appears very robust and informative (sensitivity 99.99%), specific for CRC (specificity 100%) from early to metastatic stages. Multiple studies have investigated the use of single or combined DNA methylation-based biomarkers for diagnostic purposes. 8 The performance ability of SEPT9 and VIM, the only two commercially available methylation biomarkers, to identify CRC/adenomas greatly varies depending on the experimental design. However, combining both the markers into a panel could improve the diagnostic accuracy and achieve higher clinical sensitivity. Not only our results are consistent with this observation but the performance ability of most of our biomarkers outperforms that of commercially available ones.
Importantly, this set of markers could be detected in CRC patients even through non-invasive techniques, as we identified hypermethylated tumoral DNA both in stool and plasma samples of CRC patients. Overall, the panel shows a good diagnostic and prognostic value even in the non-invasive assessment, strengthening its potential value in screening and follow-up of CRC patients. Previously, three selected markers (AGTR1, WNT2, SLIT2) were validated in stool DNA samples from CRC patients, showing a sensitivity of 21%, 40% and 52%, respectively. 27 A panel of these genes reached a sensitivity of 78%, based on the criteria that at least one of the genes was methylated. In comparison, our three selected biomarkers performed better in terms of sensitivity, with a percentage of samples showing >1% of methylation, ranging
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from 62.5% to 79.2%. Based on a similar criterion, the panel of our selected markers guaranteed an overall sensitivity of 87.5%. We conclude that, even in these samples, the tested CpG islands resulted excellent tumor markers despite the technical difficulties related to a biological challenging matrix, such as stool. Nevertheless, we acknowledge the exploratory nature of our analyses in a limited stool dataset from patients who had already received a CRC diagnosis. Future studies are warranted to assess the sensitivity and specificity of the loci identified in this work in stool DNA from asymptomatic individuals and early stage disease.
Concerning cell free DNA samples, two markers (GRIA4 and SLC8A1), were able to distinguish NED patients from metastatic and CEA-low from CEA-high. Indeed, methylation alterations displayed a negative predictive value higher than CEA (as demonstrated by the three NED patients with elevated CEA levels but not hypermethylated DNA). The absence of alterations observed in the low-CEA subgroup might be due to specific biologic features of these tumors, impairing the release of circulating markers (e.g., welldifferentiated status of neoplastic cells and absence of vascular network). However, the limited sensitivity of the techniques employed to assess methylation could have yielded false negative results. Indeed, we acknowledge that the current digital PCR technique may have limited sensitivity for cases with low tumor burden, since the assays was designed for monitoring purposes (not early detection) privileging highly linear quantification, instead of high sensitivity. 28 Further assay improvements are therefore warranted for the early detection setting. Moreover, studies with larger number of patient plasma samples and controls from healthy individuals are required to establish and exploit the potential of our markers in liquid biopsies.
In addition to identifying potentially new powerful biomarkers (only partially already correlated with cancer, see Supporting Information Table S10), in CRC early diagnosis and traceability of minimal residual disease, our study has highlighted the biological processes mainly affected by early methylation alterations in colon carcinogenesis. In fact, as shown in Figure 4 , the crosstalk between tumor cells and surrounding environment resulted particularly involved, in terms of membrane receptors, solute transporters and cell adhesion molecules. Functional annotation analysis has highlighted the enrichment of protocadherins, [29] [30] [31] [32] [33] integrins, 34 members of the solute carrier family [35] [36] [37] [38] [39] [40] and, extensively, G-protein coupled receptors involved in the transduction of neuroactive signals. 41, 42 Silencing of genes coding for protocadherins (PCDHs) by means of promoter hypermethylation, such as PCDH10 in different carcinomas 29, 30 and PCDH8 in breast cancer, 31 has been shown in several cancer types. In particular, it has been demonstrated that a cluster of PCDHs located on chromosome 5q31 undergoes a mechanism of long range epigenetic silencing (LRES) by hypermethylation. 32 47 silencing of tumor suppressor genes by this mechanism to appears a emerges as a common feature in human cancer. 33 The list of genes reported in Supporting Information Table S7 also highlights the involvement of several carriers, including many members of the solute carrier family (SLC). These genes, unlike PCDHs, are located on different chromosomes, but their common alteration suggests a combinatorial control, a mechanism well known in the regulation of gene expression. Indeed, methylation-mediated silencing of solute carriers was already reported in CRC, lung, prostate (SLC5A8), [35] [36] [37] breast and gastric cancers (SLC19A3) 38, 39 and gliomas (SLC22A18). 40 Functional studies will clarify the role of the epigenetic alterations identified in our study, especially considering that over 70% of hypermethylated islands resulted in downstream downregulation (Supporting Information Fig. S3 ). Remarkably, almost all these molecules are located at membrane or extracellular matrix level (see Fig. 3 ), therefore also potential optimal therapeutic targets. FDN: Supervision on methylBEAMing assay and analysis on ctDNA from plasma samples and stool DNA.
PZ: Supervision on experiments conducted on tissues and feces samples and related analyses.
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